Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factor

Leukemia Research

Volumn 24, Issue 3, 2000, Pages 243-248

  Akashi, Koichi ^a   Eto, Tetsuya ^a   Shibuya, Tsunefumi ^a   Shimoda, Kazuya ^a   Harada, Mine ^a   Niho, Yoshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Aclarubicin; Differentiation; Granulocyte colony stimulating factor; Myelodysplastic syndrome

Indexed keywords

ACLARUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLONY FORMATION; DNA SYNTHESIS; FEMALE; HUMAN; KARYOTYPE; LEUKEMIA CELL; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; STEM CELL;

ACLARUBICIN; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIFFERENTIATION; DRUG SYNERGISM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0033950026     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00175-7     Document Type: Article

References (19)

1. Kerkhofs H., Hermans J., Haak H.L., Leeksma C.H. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol. 65:1987;73.
2. Tricot G., Boogaerts M.A., De Wolf-Peeters C., Van den Berghe H., Verwilghen R.L. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br. J. Haematol. 59:1985;659.
3. Hirai H., Kobayashi Y., Mano H., Hagiwara K., Maru Y., Omine M. et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature. 327:1987;430.
4. Negrin R.S., Haeuber D.H., Nagler A., Kobayashi Y., Sklar J., Donlon T. et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 76:1990;36.
5. Mizuno S., Akashi K., Hirota Y., Gyoten S., Matsumoto I., Harada M. et al. Filgrastim treatment of leukaemic transformation in myelodysplastic syndrome. Lancet. 341:1993;1475.
6. Akashi K., Harada M., Shibuya T., Eto T., Takamatsu Y., Teshima T. et al. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34- blasts from acute myelogenous leukemia. Blood. 78:1991;197.
7. Schwartz E.L., Brown B.J., Nierenburg M., Marsh J.C., Sartorelli A.C. Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation. Cancer Res. 43:1983;2725.
8. Shibuya T., Teshima T., Harada M., Taniguchi S., Okamura T., Okamura S. et al. Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin. Leuk. Res. 14:1990;161.
9. Harada M., Shibuya T., Teshima T., Murakawa M., Okamura T., Niho Y. et al. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes. Leuk. Res. 17:1993;629.
10. Tricot G., De Bock R., Dekker A.W., Boogaerts M.A., Peetermans M., Punt K., Verwilghen R.L. Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes. Br. J. Haematol. 58:1984;231.
11. Shibuya T., Morioka E., Taniguchi S., Ohhara N., Okamura S., Niho Y. Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A. Leuk. Res. 11:1987;851.
12. Eto T., Akashi K., Harada M., Shibuya T., Takamatsu Y., Teshima T., Niho Y. Biological characteristics of CD7 positive acute myelogenous leukaemia. Br. J. Haematol. 82:1992;508.
13. Makino S., Harada M., Akashi K., Taniguchi S., Shibuya T., Inaba S., Niho Y. A simplified method for cryopreservation of peripheral blood stem cells at -80°C without rate-controlled freezing [see comments]. Bone Marrow Transpl. 8:1991;239.
14. Shimoda K., Okamura S., Harada N., Ikematsu W., Kondo S., Kawasaki C. et al. Granulocyte colony-stimulating factor receptors on human acute leukemia: biphenotypic leukemic cells possess granulocyte colony-stimulating factor receptors. Cancer Res. 52:1992;3052.
15. Akashi K., Shibuya T., Harada M., Takamatsu Y., Uike N., Eto T., Niho Y. Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells. J. Clin. Invest. 88:1991;223.
16. Ikebuchi K., Clark S.C., Ihle J.N., Souza L.M., Ogawa M. Granulocyte colony-stimulating factor enhances interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 85:1988;3445.
17. Nakahata T., Ogawa M. Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc. Natl. Acad. Sci. USA. 79:1982;3843.
18. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature. 339:1989;27.
19. Im T., Yamane T., Mugitani A., Hiyoshi M., Park K., Tatsumi N. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Int. J. Hematol. 60:1994;215.